Wang Tianxi, Kaneko Satoshi, Kriukov Emil, Alvarez David, Lam Enton, Wang Yidi, La Manna Sara, Marasco Daniela, Fernandez-Gonzalez Angeles, Mitsialis S Alex, Kourembanas Stella, Stahl Andreas, Chen Mei, Xu Heping, Baranov Petr, Cai Guoshuai, von Andrian Ulrich H, Sun Ye
Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Department of Ophthalmology, The Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
Mol Ther. 2024 May 1;32(5):1425-1444. doi: 10.1016/j.ymthe.2024.03.025. Epub 2024 Mar 19.
Pathological ocular angiogenesis has long been associated with myeloid cell activation. However, the precise cellular and molecular mechanisms governing the intricate crosstalk between the immune system and vascular changes during ocular neovascularization formation remain elusive. In this study, we demonstrated that the absence of the suppressor of cytokine signaling 3 (SOCS3) in myeloid cells led to a substantial accumulation of microglia and macrophage subsets during the neovascularization process. Our single-cell RNA sequencing data analysis revealed a remarkable increase in the expression of the secreted phosphoprotein 1 (Spp1) gene within these microglia and macrophages, identifying subsets of Spp1-expressing microglia and macrophages during neovascularization formation in angiogenesis mouse models. Notably, the number of Spp1-expressing microglia and macrophages exhibited further elevation during neovascularization in mice lacking myeloid SOCS3. Moreover, our investigation unveiled the Spp1 gene as a direct transcriptional target gene of signal transducer and activator of transcription 3. Importantly, pharmaceutical activation of SOCS3 or blocking of SPP1 resulted in a significant reduction in pathological neovascularization. In conclusion, our study highlights the pivotal role of the SOCS3/STAT3/SPP1 axis in the regulation of pathological retinal angiogenesis.
Proc Natl Acad Sci U S A. 2015-8-18
Biomed Pharmacother. 2024-9
Front Pharmacol. 2025-5-13
Front Endocrinol (Lausanne). 2025-3-4
Invest Ophthalmol Vis Sci. 2024-10-1
Curr Issues Mol Biol. 2023-5-13
Acta Biochim Biophys Sin (Shanghai). 2022-10-25
Pharmaceuticals (Basel). 2022-4-9